

## Supporting Information

### Photoaffinity labelling-based chemoproteomic strategy identifies PEBP1 as the target of ethyl gallate against macrophage activation

Wei Yu<sup>a</sup>, Min Liao<sup>b</sup>, Yang Chen<sup>a</sup>, Rui Xue<sup>a</sup>, Xiao-Meng Shi<sup>b</sup>, Dan Liu<sup>b</sup>, Fang-Fang Zhuo<sup>b</sup>, Hui Tang<sup>a</sup>, Zhi-Yuan Lu<sup>c</sup>, Peng-Fei Tu<sup>b</sup>, Bo Han<sup>a\*</sup>, Xin Jia<sup>a\*</sup>, Ke-Wu Zeng<sup>a, b\*</sup>

<sup>a</sup>*School of Chemistry and Chemical Engineering/School of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Shihezi University, Shihezi 832003, China*

<sup>b</sup>*State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China*

<sup>c</sup>*Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250062, China*

\*Correspondence: Bo Han ([524683221@qq.com](mailto:524683221@qq.com)); Xin Jia ([jjaxin@shzu.edu.cn](mailto:jjaxin@shzu.edu.cn)); Ke-Wu Zeng ([ZKW@bjmu.edu.cn](mailto:ZKW@bjmu.edu.cn)).

## Table of contents

25

### 26 I. Supplementary materials and methods

27 1. Chemicals and reagents

28 2. The synthesis of ethyl gallate probe (AD-EG)

29 3. Cell culture

30 4. MTT assay

31 5. Nitric oxide (NO) assay

32 6. Enzyme-linked immunosorbent assay (ELISA)

33 7. In-gel fluorescence labelling

34 8. Pull-down assay

35 9. LC-MS analysis

36 10. Drug affinity responsive target stability (DARTS)

37 11. Cellular thermal shift assay (CETSA)

38 12. PEBP1 expression and purification

39 13. Surface plasmon resonance (SPR) assay

40 14. Isothermal titration calorimetry (ITC) analysis

41 15. Tryptophan fluorescence quenching study

42 16. Determination of EG-binding site on PEBP1

43 17. Molecular Docking

44 18. Hydrogen-deuterium exchange mass spectrometry (HDXMS) analysis

45 19. Co-immunoprecipitation (co-IP) analysis

46 20. Immunofluorescence assay

47 21. Transient transfection with PEBP1 siRNA

48 22. Western blot analysis

49 23. Statistical analysis Results

## 50 II. Supplementary figures

51 **Figure S1.**  $^1\text{H}$  NMR spectrum of AD-EG

52 **Figure S2.**  $^{13}\text{C}$  NMR spectrum of AD-EG

53 **Figure S3.** MS of AD-EG

54 **Figure S4.**  $^1\text{H}$ - $^1\text{H}$  COSY spectra for AD-EG

55 **Figure S5.** HMBC spectra for AD-EG

56 **Figure S6.** HSQC spectra for AD-EG

57 **Figure S7.** PEBP1 serves as a cellular target of EG

58 **Figure S8.** ITC analysis for the binding of EG with PEBP1<sup>D70A</sup> (A), PEBP1<sup>Y120F</sup> (B) and  
59 PEBP1<sup>D70A/Y120F</sup> (C) mutants

60 **Figure S9.** EG inhibited NF- $\kappa$ B pathway activation

61 **Figure S10-12** Whole uncropped images of the original western blots.

## 62 III. Supplementary references

63

## 64 I. Supplementary materials and methods

### 65 1. Chemicals and reagents

66 Ethyl gallate (C<sub>9</sub>H<sub>10</sub>O<sub>5</sub>) was purchased from Yuanye Bio-Technology (Shanghai, China) and  
67 confirmed with MS, <sup>13</sup>C-NMR and <sup>1</sup>H-NMR data. The purity is above 98 % by HPLC analysis.  
68 5-TAMRA-azide was purchased by Jena Bioscience (Jena, Thuringia, Germany). 4,6-  
69 diamidino-2-phenylindole (DAPI), tris (2-carboxyethyl) phosphine (TCEP), tris [(1-benzyl-1*H*-  
70 1,2,3-triazol-4-yl) methyl] amine (TBTA), lipopolysaccharides (LPS), and 3-(3-(but-3-yn-1-yl)-  
71 3*H*-diazirin-3-yl) propanoic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
72 Biotin-PEG3-azide was obtained from AAT Bioquest (Mercury Drive Sunnyvale, CA, USA).  
73 Pronase, *E. coli* DH5α and *E. coli* BL21 (DE3) were purchased from Solarbio (Beijing, China).  
74 Anti-PEBP1 antibody (ab76582) and anti-p-PEBP1 (Ser153) antibody (EP2845Y) were  
75 obtained from Abcam (Cambridge, Cambs, UK). Anti-p-NF-κB p65 (Ser536) antibody (3033S),  
76 anti-NF-κB p65 (8242S), anti-IKKβ antibody (8493P), anti-p-IKKα/β antibody (2694T), anti-  
77 IκBα antibody (4814T), anti-p-IKB-α (Ser32) antibody (2859T), and anti-HA-Tag (3724) were  
78 purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-Raf-1 (66592-1-Ig)  
79 antibody, HRP-conjugated goat anti-rabbit IgG antibody (SA00001-2), and anti-GAPDH HRP-  
80 conjugate antibody (60004-1-Ig) were purchased from Proteintech (Chicago, IL, USA). NO  
81 assay kit was purchased from Nanjing Jiancheng Bio-Engineering Institute (Nanjing, Jiangsu,  
82 China). BCA protein assay reagent was purchased from TransGen Biotech (Beijing, China).  
83 TNF-α and IL-6 ELISA kits were purchased from ExCell Biology (Shanghai, China).

84

### 85 2. The synthesis of ethyl gallate probe (AD-EG)

86 The synthetic route of alkyne/diazirine-double labelled EG probe (AD-EG) is shown in Figure  
87 1A. 1-benzoyl-4-piperidinemethanamine HCl (120 μL) and 3-(3-(but-3-yn-1-yl)-3*H*-diazirin-3-  
88 yl) propanoic acid (80.5 mg) were dissolved in dichloromethane for 24 h. Next, EG (143.2 mg)  
89 and NaH (34.6 mg) were dissolved in tetrahydrofuran. Next, added 164.5 mg N,N'-  
90 Dicyclohexylcarbodiimide (DCC) and 105.6 mg 4-dimethylaminopyridine (DMAP) to the  
91 above reaction mixture and stirred in darkness at 25 °C for 24 h, purified through silica gel  
92 column chromatography, and ultimately eluted with ethyl acetate: petroleum ether (1 : 10) to

93 get AD-EG as white solid with 28.3 % yield. The structure of AD-EG was verified by MS, <sup>1</sup>H-  
94 NMR (600 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.53  
95 (d, J = 1.9 Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 2.47 (t, J = 7.3 Hz, 2H),  
96 2.20 (t, J = 7.7 Hz, 2H), 2.07 – 2.03 (m, 5H), 1.84 (t, J = 7.7 Hz, 2H), 1.74 (d, J = 7.3 Hz, 1H),  
97 1.68 (t, J = 7.4 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 177.16, 170.73,  
98 165.85, 145.27, 140.11, 137.81, 122.51, 116.31, 114.48, 82.48, 69.56, 69.32, 61.23, 32.16,  
99 28.50, 27.70, 14.28, 13.25, 1.03, 0.00.

100

### 101 **3. Cell culture**

102 RAW264.7 mouse macrophages were provided from Peking Union Medical College Cell  
103 Bank (Beijing, China). The cells were cultivated in Dulbecco's Modified Eagle Medium  
104 (DMEM) containing 10 % FBS and 1 % penicillin-streptomycin solution at 37 °C with 5 % CO<sub>2</sub>.

105

### 106 **4. MTT assay**

107 The cells were seeded at a density of 5 × 10<sup>4</sup> /well in 96-well plates overnight, and next LPS  
108 (1 µg/mL) was added with or without EG (12.5, 25 and 50 µM). After 24 h, 0.5 mg/mL MTT  
109 solution was added and cells were incubated under a temperature of 37 °C for 4 h. Formazan  
110 crystals were dissolved in 200 µL DMSO. Utilizing a microplate reader (Tecan Austria GmbH,  
111 Männedorf, Switzerland), the formazan concentration was assessed through detecting the  
112 absorbance at 570 nm.

113

### 114 **5. Nitric oxide (NO) assay**

115 The generation of NO was determined with NO assay kit. RAW264.7 cells were treated with  
116 1 µg/mL LPS with or without EG (12.5, 25 and 50 µM) for 24 h. Subsequently, the cell  
117 supernatant was mixed with Griess reagent for 10 min at 1 : 1 ratio for incubation at room  
118 temperature. The value of absorbance was determined at 540 nm through microplate reader  
119 (Tecan Austria GmbH, Männedorf, Switzerland).

120

### 121 **6. Enzyme-linked immunosorbent assay (ELISA)**

122 TNF- $\alpha$  and IL-6 were detected using ELISA assay. Different concentrations of EG (12.5, 25  
123 and 50  $\mu$ M) were applied to RAW264.7 cells in the presence of 1  $\mu$ g/mL LPS. For the further  
124 determination, the cell supernatant was collected at various time points (4 h for TNF- $\alpha$  assay,  
125 8 h for IL-6 assay) using commercial ELISA kits. Briefly, the IL-6/TNF- $\alpha$  standard solutions  
126 and samples were added into 96-well plates that were coated with specific monoclonal  
127 antibody. Subsequently, the plates were exposed to biotin-anti-conjugated cytokine  
128 antibodies and tested with streptavidin-peroxidase-conjugated anti-rabbit antibodies.  
129 Ultimately, the stop solution was added and the ODs were measured at 450 nm on a  
130 microplate reader (Tecan Austria GmbH, Männedorf, Switzerland). The concentration of TNF-  
131  $\alpha$ /IL-6 was detected in accordance with the standard curve fitted through IL-6/TNF- $\alpha$  standard  
132 solutions.

133

## 134 **7. In-gel fluorescence labelling**

135 RAW264.7 cells were inoculated with various concentrations of AD-EG (25, 50 and 100  $\mu$ M)  
136 for 4 h. Next, the cells were washed two times using PBS and they were exposed to UV (365  
137 nm) for 10 min. Cells were lysed in NP-40 buffer (Beyotime, Shanghai, China) supplemented  
138 1 % protease inhibitor and adjusted to a same volume and concentration utilizing NP-40 lysis  
139 buffer as previously described<sup>1-3</sup>. In short, cell lysates containing 1 mg proteins were  
140 successively mixed with 3  $\mu$ L 5-TAMRA-azide (20 mM in DMSO), 24  $\mu$ L TCEP (14.4 mg/mL),  
141 and 3.5  $\mu$ L TBTA (34 mM in DMSO). The click chemistry was initiated by 11.6  $\mu$ L CuSO<sub>4</sub> (50  
142 mM). The reaction was incubated for 1 h at room temperature. The protein pellets were  
143 gathered with 6000 g centrifugation and washed using cold methanol. Then, the samples  
144 were heated in 1.2 % SDS at 85 °C for 10 min and separated by SDS-PAGE. The  
145 fluorescence scanning was conducted with chemiluminescent gel imager scanner  
146 (ChemiDoc XRS System, Hercules, CA, USA). For the competitive labelling assay,  
147 RAW264.7 cells were incubated with EG (50 and 100  $\mu$ M) for 1 h before incubating with AD-  
148 EG (50  $\mu$ M).

149

## 150 **8. Pull-down assay**

151 For targets identification in situ labelling experiments, AD-EG was incubated with RAW264.7  
152 cells on the basis of stable isotope labelling with amino acids in cell culture (SILAC)  
153 proteomics. RAW264.7 cells were cultivated in medium involving either  $^{13}\text{C}_6^{15}\text{N}_2$ -  
154 Lysine/ $^{13}\text{C}_6^{15}\text{N}_4$  L-Arginine (Heavy) or  $^{12}\text{C}_6^{14}\text{N}_2$ -Lysine/ $^{12}\text{C}_6^{14}\text{N}_4$  L-Arginine (Light). Cells were  
155 grown in heavy or light labelled-medium for at least 6 cell passages to reach 96 %  
156 incorporation. RAW264.7 cells (Heavily- or Light-labelled) were stimulated with LPS (1  
157  $\mu\text{g}/\text{mL}$ ) for 6 h, followed by treatment with AD-EG (50  $\mu\text{M}$ ). At the same time, the excess EG  
158 (100  $\mu\text{M}$ ) for competitive binding was added into light-labelled cells and then further  
159 inoculated at 37 °C for 4 h. The click chemistry with biotin-PEG3-azide was performed as  
160 above described. The proteins were collected by centrifugation and resuspended in 0.2 %  
161 SDS/PBS. Then streptavidin beads were mixed with samples and incubated at room  
162 temperature for 3 h. Eventually, the captured proteins on the streptavidin beads were  
163 digested by trypsin and determined with LC-MS/MS (NanoLC-LTQ Velos pro MS, Thermo,  
164 Waltham, MA, USA). The *p*-value (< 0.01) and protein fold change (> 1.2) were considered  
165 to indicate a differentially abundant protein<sup>4</sup>.

166

## 167 **9. LC-MS analysis**

168 The peptides were separated in C18 reversed-phase column. Elution buffer A and B were  
169 0.1 % and 0.2 % formic acid in water and acetonitrile, respectively. The gradient elution  
170 procedure was 2 % - 40 % B for 70 min; 40 % - 95 % B for 5 min; 95 % B for 20 min. The  
171 eluent was introduced to the MS at 300 nL/min. The parameters of MS are as below: scan  
172 spectra, 350 to 2000 m/z; maximum IT, 50 ms; HCD Collision Energy, 35 %; resolution, 60000;  
173 Target FDR for PSMs, 0.01. The analysis of MS data was conducted through Proteome  
174 Discoverer (version 1.4) software with SEQUEST (Thermo, Waltham, MA, USA).

175

## 176 **10. Drug affinity responsive target stability (DARTS)**

177 DARTS was performed as previously described<sup>5, 6</sup>. RAW264.7 cells were lysed with NP-40  
178 Lysis Buffer (Beyotime, Shanghai, China). Lysates were diluted with 10×TNC buffer (50 mM  
179 NaCl, 10 mM  $\text{CaCl}_2$ , 50 mM Tris-HCl, pH 8.0) and incubated with different concentrations of  
180 EG (10, 50 and 100  $\mu\text{M}$ ) at room temperature for 1 h. Subsequently, 5  $\mu\text{g}/\text{mL}$  of pronase was

181 added and incubated at room temperature for 20 min in 1 × TNC buffer. After adding the SDS  
182 loading buffer, the reactions were terminated, followed by a specific anti-PEBP1 antibody  
183 detection via western blot.

184

## 185 **11. Cellular thermal shift assay (CETSA)**

186 CETSA was adapted from previous research to identify the ligand-target engagement<sup>7,8</sup>. For  
187 living cells CETSA experiment, RAW264.7 cells were pretreated with EG (50 μM) or DMSO  
188 for 3 h at room temperature and harvested in PBS with 1 % protease inhibitor. Then, cells  
189 were classified into ten groups and heated at gradient temperature (43 - 61 °C) for two min  
190 respectively with T100 Thermal Cycle (Bio-Rad, Hercules, CA, USA). Kinase buffer (CST,  
191 Beverly, MA, USA) was added to the samples and repeated freeze-thaw in liquid nitrogen.  
192 The lysate was collected and analyzed through western blot with a specific anti-PEBP1  
193 antibody. For the cell lysate CETSA experiments, RAW264.7 cells were gathered and  
194 repeatedly frozen and thawed in liquid nitrogen. Subsequently, the cell lysates were classified  
195 into two groups, one as the control group (DMSO), and the other group was inoculated using  
196 EG (50 μM) for 1 h at 37 °C. The lysates were heated and analyzed as above described in  
197 living cells experiment.

198

## 199 **12. PEBP1 expression and purification**

200 His-PEBP1, His-PEBP1<sup>D70A</sup>, His-PEBP1<sup>Y120F</sup> and His-PEBP1<sup>D70A/Y120F</sup> plasmids were  
201 expressed in *E.coli* BL21 (DE3) cells. The recombinant proteins were induced by isopropyl-  
202 β-D-1-thio-galactopyranoside (0.5 mM, IPTG) at 16 °C in 120 rpm for 18 h. The cells were  
203 gathered by centrifugation at 4000 rpm for 25 min under a temperature of 4 °C. The cells  
204 were lysed and the supernatant was loaded onto Ni-NTA resin (Thermo, Waltham, MA, USA)  
205 with HEPES buffer (a gradient of 10-250 mM imidazole, 20 mM HEPES, 250 mM NaCl) to  
206 remove impurities. The proteins were concentrated via centrifugal filtration (Amicon Ultra-10,  
207 Millipore, Waltham, MA, USA) and dissolved in PBS buffer for confirmation with Coomassie  
208 brilliant blue staining.

209

## 210 **13. Surface plasmon resonance (SPR) assay**



211 The analysis of interaction between PEBP1 and EG was implemented with Biacore T200  
212 system (GE Healthcare, Uppsala, Sweden). The carboxymethylation 5 (GE Healthcare,  
213 Uppsala, Sweden) sensor chip was immobilized with recombinant PEBP1 protein (120 µg/mL)  
214 by amine coupling reaction (acetate, pH 4.5). Different concentrations of EG (0.39 to 12.5  
215 µM) in PBS (containing 5 % DMSO) were injected into the sensor chip. The analysis of data  
216 was conducted through Biacore evaluation software (GE Healthcare, Uppsala, Sweden).

217

#### 218 **14. Isothermal titration calorimetry (ITC) analysis**

219 ITC was carried out using a MicroCal PEAQ-ITC200 (Malvern Instruments, Malvern, UK) at  
220 25 °C. PEBP1 protein (100 µM) and EG (1 mM) were prepared in PBS (pH 7.4, 0.1 % DMSO).  
221 PEBP1 protein solution (100 µM) was placed in the calorimeter sample cell (280 µL), and EG  
222 solution (1 mM) was put into injection syringe. In the process of titration, an initial injection of  
223 EG (0.4 µL) was followed by 19 successive injections of 2 µL with a 150 s interval. Ultimately,  
224 the binding parameters, including the association constant ( $K_D$ ), enthalpy value ( $\Delta H$ ), and  
225 entropy value ( $\Delta S$ ), were analyzed by the Origin 9.0.

226

#### 227 **15. Tryptophan fluorescence quenching study**

228 Recombinant PEBP1 protein was titrated utilizing the vehicle or EG (1-500 µM) in a quartz  
229 plate (96-well). The fluorescence intensities after continuous addition of EG solution were  
230 detected via setting excitation wavelength (280 nm) and emission wavelengths from 300 to  
231 500 nm at 1 nm increment with fluorescence spectrophotometer (PerkinElmer, Waltham, MA,  
232 USA). Then, the intensities of fluorescence were corrected by the buffer contribution.

233

#### 234 **16. Determination of EG-binding site on PEBP1**

235 Recombinant PEBP1 protein was inoculated with DMSO or AD-EG (50 µM) at 37 °C for 2 h,  
236 which was exposed to 365 nm UV for 10 min on ice. The SDS loading buffer was added into  
237 samples and heated at 98 °C for 10 min. Subsequently, the samples were separated with  
238 SDS-PAGE. The proteins were digested with trypsin and analyzed with Q-Exactive HF mass  
239 spectrometer coupled with an UltiMate 3000 RSLCnano System (Thermo Fisher Scientific,  
240 Waltham, MA, USA). The samples were bound onto a trap column (3 µm) packed with

241 ReproSil-Pur C18-AQ (100  $\mu\text{m}$ , 12 cm). The peptides were isolated on a C18 column (3  $\mu\text{m}$ )  
242 packed with ReproSil-Pur C18-AQ (75  $\mu\text{m}$ , 12 cm) and eluted as the below gradient through  
243 phase B (0.1 % formic acid in acetonitrile) at the flow rate of 300 nL/min: 0 - 70 min (2 %-40  
244 %), 70 - 75 min (40 % - 95 %), 75 - 95 min (95 %). Mass spectrometers were operated in  
245 positive ionization mode with the MS parent scan of a mass range from 350 to 1500 m/z with  
246 resolution 60000 to 200 m/s. RAW files were analyzed through Proteome Discoverer (PD)  
247 2.2 (Thermo Fisher Scientific, Waltham, MA, USA) according to the database of ratus UniProt  
248 FASTA. The maximum missed cleavage sites is 2. Fragment mass tolerance was 0.02 Da  
249 and precursor mass tolerance was 10 ppm. Oxidation at methionine was set as dynamic  
250 modification, carbamidomethylation at cysteine was set as static modification, and 318.1098  
251 was set as dynamic modification. The percolator was used to filter the results with FDR < 1  
252 %.

253

## 254 **17. Molecular Docking**

255 The entire docking process was performed using Induced Fit Docking module of Schrodinger  
256 2018. From RCSB Protein Data Bank, PEBP1 protein crystal structure (PDB code: 1BD9)  
257 was downloaded. The potential receptor binding site was predicted by the Schrödinger  
258 SiteMap component. The grid box around the active site was generated using Receptor Grid  
259 Generation module, with the coordinate values of center\_x = -17.332, center\_y = 32.139,  
260 center\_z = 44.032, and dock ligand with length  $\leq 20$  Å. EG and PEBP1 were docked with  
261 Induced Fit docking module to obtain precise binding conformation. The Glide XP was chosen  
262 for docking precision. Finally, Pymol software (Schrödinger, LLC, Palo Alto, CA, USA) was  
263 used to show the interaction types of docked PEBP1 protein with EG ligand.

264

## 265 **18. Hydrogen-deuterium exchange mass spectrometry (HDXMS) analysis**

266 HDXMS experiment was carried out as previously described<sup>9</sup>. Briefly, deuterium labelling was  
267 initiated with a 20-fold dilution into D<sub>2</sub>O buffer of a pre-equilibrated aliquot of PEBP1 protein  
268 in the presence or absence of EG at 37 °C for 30 min. The labelling reaction was quenched  
269 through adding concentrated hydrochloric acid at specified time points (0.08, 0.25, 1, 30, 60,  
270 and 240 min). Subsequently, samples were injected and online digested by a Waters  
271 ENZYMATE BEH pepsin column (2.1  $\times$  30 mm, 5  $\mu\text{m}$ ). The peptides were trapped and  
272 desalted on a VanGuard Pre-Column trap (ACQUITY UPLC BEH C18, 1.7  $\mu\text{m}$ ) for 3 min,

273 eluted in the trap by 15 % acetonitrile at 100  $\mu$ L/min flow rate, and isolated through an  
274 ACQUITY UPLC BEH C18 column (1.0  $\times$  100 mm, 1.7  $\mu$ m). The relative deuterium content  
275 of all peptides was calculated by subtracting the mass of the undertreated control sample  
276 from that of the deuterium-labelled sample.

277

### 278 **19. Co-immunoprecipitation (co-IP) analysis**

279 The cells were transfected with HA-PEBP1 for 48 h, and inoculated with 1  $\mu$ g/mL LPS and  
280 treated in the presence and absence of EG (50  $\mu$ M) for 1 h. The cells were lysed and collected  
281 via centrifugation at 10000 rpm for 15 min. Anti-HA-tag antibody-conjugated magnetic beads  
282 were added into cell lysate for 4 h at 4  $^{\circ}$ C. Then, the immunoprecipitated proteins were  
283 separated by SDS-PAGE and determined with western blot.

284

### 285 **20. Immunofluorescence assay**

286 RAW264.7 cells were seeded on uncoated confocal dish, and stimulated with LPS (1  $\mu$ g/mL)  
287 and EG (50  $\mu$ M) for 1 h. The cells were fixed through 4 % (w/v) paraformaldehyde for 20 min,  
288 and subsequently permeabilized by 0.5 % Triton X-100 for 0.5 h. The cells were blocked with  
289 5 % BSA for 1 h. Anti-NF- $\kappa$ B p65 antibody was added for incubation overnight under a  
290 temperature of 4  $^{\circ}$ C. Next, the cells were incubated with the secondary antibody labelled by  
291 Dylight 594 (1 : 200) for 1 h at 37  $^{\circ}$ C. After washes with PBS, the cells were incubated with  
292 20  $\mu$ g/mL DAPI for 20 min at 37  $^{\circ}$ C. The fluorescence (340 nm/488 nm for DAPI; 594 nm/618  
293 nm for Dylight 594) was visualized via Zeiss LSM880 (Zeiss, Oberkochen, Germany).

294

### 295 **21. Transient transfection with PEBP1 siRNA**

296 For siRNA knockdown, cells were transfected by lipofectamine RNAimax (Invitrogen,  
297 Carlsbad, CA, USA) with NC or PEBP1 siRNA (Gene Pharma, Shanghai, China) in Opti-  
298 MEM medium. After 6 h, the cells were washed with DMEM medium and further cultured for  
299 48 h. The PEBP1-siRNA sequence was shown as listed in Table 1.

300

301

302

303

304  
305

**Table 1** SiRNA sequences for transfection.

Name	Sequence
<i>PEBP1</i> siRNA	5'-3' (sense) GAUCCUGGGAAACUCUACATT 5'-3' (antisense) UGUAGAGUUUCCCAGGAUCTT
Negative siRNA	5'-3' (sense) UUCUCCGAACGUGUCACGUTT 5'-3' (antisense) ACGUGACACGUUCGGAGAATT

306

## 22. Western blot analysis

307 RAW264.7 cells were collected after treatment and lysed in RIPA with 1 % protease  
308 suppressor. The concentration of protein was examined utilizing BCA protein assay reagent.  
309 SDS loading buffer was added into protein samples and subsequently heated under a  
310 temperature of 98 °C for 10 min. Next, the proteins were isolated with 10-15 % SDS-PAGE,  
311 and transferred to PVDF membrane. Afterwards, the membrane was blocked in 5 % (w/v)  
312 skimmed milk at 37 °C for 30 min, and incubated with primary antibodies overnight at 4 °C  
313 and HRP-conjugated secondary antibodies for 1 h at 37 °C. Finally, the membranes were  
314 visualized by ECL (Thermo, Waltham, MA, USA), and scanned with Tanon 5200 Imaging  
315 Analysis System (Tanon, Shanghai, China).

316

## 23. Statistical analysis Results

317 The data were presented as means  $\pm$  standard error of mean (SEM). Statistical analysis was  
318 performed with Student's t-test of variance (ANOVA) using GraphPad Prism 8.0.  $P < 0.05$   
319 was considered as statistically significant.

321

322

323

324

325

326

## II. Supplementary figures




Fig. S1  $^1\text{H}$  NMR spectrum of AD-EG.

EG-pro-1/2





Fig. S2 <sup>13</sup>C NMR spectrum of AD-EG.

乙酯MS #50 RT: 0.68 AV: 1 NL: 4.13E3  
T: FTMS + p ESI Full ms [100.0000-1200.0000]



乙酯MS #50 RT: 0.68 AV: 1 NL: 6.07E4  
T: FTMS + p ESI Full ms [100.0000-1200.0000]






Fig. S3 MS of AD-EG.




**Fig. S4  $^1\text{H}$ - $^1\text{H}$  COSY spectra for AD-EG.**







**Fig. S5 HMBC spectra for AD-EG.**




**Fig. S6 HSQC spectra for AD-EG.**




**Fig. S7 PEBP1 serves as a cellular target of EG.** (A-B) The low cytotoxicity of EG and AD-EG in RAW264.7 cells. (C-D) EG or AD-EG inhibited the level of NO production. (E) Binding affinity analysis of EG with PEBP1 determined by SPR. (F) Typical ITC binding isotherms for the EG interaction of PEBP1. Data are expressed as mean  $\pm$  SEM for four individual experiments. \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , \* $P < 0.05$ .



**Fig. S8** ITC analysis for the binding of EG with PEBP1<sup>D70A</sup> (A), PEBP1<sup>Y120F</sup> (B) and PEBP1<sup>D70A/Y120F</sup> (C) mutants.



**Fig. S9 EG inhibited NF- $\kappa$ B pathway activation.** (A) Total and phosphorylation expressions of IKK $\beta$ , I $\kappa$ B- $\alpha$  and NF- $\kappa$ B p65 were determined by western blot assay. (B) The nuclear translocation of NF- $\kappa$ B p65 was detected by immunofluorescence assay. Representative images were displayed with NF- $\kappa$ B p65 (red) and nucleus (blue), scale bar = 20  $\mu$ m.



**Fig. S10** Whole uncropped images of the original western blots.





Fig. S11 Whole uncropped images of the original western blots.



**Fig. S12** Whole uncropped images of the original western blots.



### III. Supplementary references

1. L. G. Chen, H. J. Wang, T. F. Ji and C. J. Zhang, *Chem. Comm.*, 2021, **57**, 5981-5984.
2. H. B. Shi, C. J. Zhang, G. Y. J. Chen and S. Q. Yao, *J. Am. Chem. Soc.*, 2012, **134**, 3001-3014.
3. X.-W. Xu, Y. Zhu, J.-Z. Song, G.-Q. Zou, Z. Zhao, Q.-L. Zheng, L.-J. Cao, G.-J. Wang, H. Wang and H.-P. Hao, *Anal. Chem.*, 2022, **94**, 10722-10729.
4. L. Yao, M. Liao, J. K. Wang, J. Wang, D. Liu, P. F. Tu and K. W. Zeng, *Anal. Chem.*, 2022, **94**, 3180-3187.
5. B. Lomenick, R. Hao, N. Jonai, R. M. Chin, M. Aghajan, S. Warburton, J. N. Wang, R. P. Wu, F. Gomez, J. A. Loo, J. A. Wohlschlegel, T. M. Vondriska, J. Pelletier, H. R. Herschman, J. Clardy, C. F. Clarke and J. Huang, *P. Natl. Acad. Sci. USA.*, 2009, **106**, 21984-21989.
6. X.-W. Zhang, N. Feng, Y.-C. Liu, Q. Guo, J.-K. Wang, Y.-Z. Bai, X.-M. Ye, Z. Yang, H. Yang, Y. Liu, M.-M. Yang, Y.-H. Wang, X.-M. Shi, D. Liu, P.-F. Tu and K.-W. Zeng, *Sci. Adv.*, 2022, **8**, eabo0789.
7. Q. Guo, Y.-C. Zhang, W. Wang, Y.-Q. Wang, Y. Liu, Z. Yang, M.-M. Zhao, N. Feng, Y.-H. Wang, X.-W. Zhang, H. Yang, T.-T. Liu, L.-Y. Shi, X.-M. Shi, D. Liu, P.-F. Tu and K.-W. Zeng, *Pharmacol. Res.*, 2022, **176**, 106046.
8. D. M. Molina, R. Jafari, M. Ignatushchenko, T. Seki, E. A. Larsson, C. Dan, L. Sreekumar, Y. H. Cao and P. Nordlund, *Science*, 2013, **341**, 84-87.
9. Y.-J. Wan, L.-X. Liao, Y. Liu, H. Yang, X.-M. Song, L.-C. Wang, X.-W. Zhang, Y. Qian, D. Liu, X.-M. Shi, L.-W. Han, Q. Xia, K.-C. Liu, Z.-Y. Du, Y. Jiang, M.-B. Zhao, K.-W. Zeng and P.-F. Tu, *Theranostics*, 2020, **10**, 797-815.